221 related articles for article (PubMed ID: 23369893)
1. Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?
Nuyts AH; Lee WP; Bashir-Dar R; Berneman ZN; Cools N
Mult Scler; 2013 Jul; 19(8):995-1002. PubMed ID: 23369893
[TBL] [Abstract][Full Text] [Related]
2. Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.
Flórez-Grau G; Zubizarreta I; Cabezón R; Villoslada P; Benitez-Ribas D
Front Immunol; 2018; 9():1169. PubMed ID: 29904379
[TBL] [Abstract][Full Text] [Related]
3. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
4. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
5. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
Lim ET; Giovannoni G
Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
[TBL] [Abstract][Full Text] [Related]
6. Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.
Xie ZX; Zhang HL; Wu XJ; Zhu J; Ma DH; Jin T
Mediators Inflamm; 2015; 2015():513295. PubMed ID: 25705093
[TBL] [Abstract][Full Text] [Related]
7. The role of regulatory T cells in multiple sclerosis.
Zozulya AL; Wiendl H
Nat Clin Pract Neurol; 2008 Jul; 4(7):384-98. PubMed ID: 18578001
[TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis and immunotherapy of multiple sclerosis.
Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells.
Serafini B; Rosicarelli B; Magliozzi R; Stigliano E; Capello E; Mancardi GL; Aloisi F
J Neuropathol Exp Neurol; 2006 Feb; 65(2):124-41. PubMed ID: 16462204
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches and cutting edge immunotherapies in multiple sclerosis.
Bauman TM; Kasper LH
Front Biosci; 2004 Sep; 9():2302-22. PubMed ID: 15353289
[TBL] [Abstract][Full Text] [Related]
12. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.
Kieseier BC; Archelos JJ; Storch M; Gold R; Hartung HP
Wien Klin Wochenschr; 1999 Sep; 111(17):728-37. PubMed ID: 10526397
[TBL] [Abstract][Full Text] [Related]
13. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
[TBL] [Abstract][Full Text] [Related]
14. Future immunotherapies in multiple sclerosis.
Blevins G; Martin R
Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
[TBL] [Abstract][Full Text] [Related]
15. The role of innate immune responses in autoimmune disease development.
Waldner H
Autoimmun Rev; 2009 Mar; 8(5):400-4. PubMed ID: 19162250
[TBL] [Abstract][Full Text] [Related]
16. Tolerogenic dendritic cells: key regulators of peripheral tolerance in health and disease.
Saei A; Hadjati J
Int Arch Allergy Immunol; 2013; 161(4):293-303. PubMed ID: 23689518
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells: friend or foe in autoimmunity?
Santiago-Schwarz F
Rheum Dis Clin North Am; 2004 Feb; 30(1):115-34. PubMed ID: 15061571
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?
Cools N; Petrizzo A; Smits E; Buonaguro FM; Tornesello ML; Berneman Z; Buonaguro L
Immunotherapy; 2011 Oct; 3(10):1203-22. PubMed ID: 21995572
[TBL] [Abstract][Full Text] [Related]
19. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.
Stasiolek M; Bayas A; Kruse N; Wieczarkowiecz A; Toyka KV; Gold R; Selmaj K
Brain; 2006 May; 129(Pt 5):1293-305. PubMed ID: 16513684
[TBL] [Abstract][Full Text] [Related]
20. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
Lisak RP
Neurology; 1988 Jul; 38(7 Suppl 2):5-8. PubMed ID: 3290714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
